UNSPSC 51401544: Pivoxazepam

This classification denotes an anxiolytic with the molecular formula C20H19ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F4ER8Z6Q3U, chemically known as 7-chloro-1,3-dihydro-3-hydroxy-5-phenyl-2h-1,4-benzodiazepin-2-one pivalate (ester) but generally known as pivoxazepam, which bears US NIH Compound Identifier 68722. European Medicines Agency schedules Pivoxazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09953MIG.

UNSPSC 51401544 Pivoxazepam is a Commodity code designating a specific benzodiazepine pharmaceutical product, yet recent state and local procurement activity under this code reflects broader pharmaceutical supply and distribution arrangements rather than pivoxazepam procurement alone. State and local buyers use this code to solicit generic multi-source pharmaceuticals, over-the-counter products, naloxone and drug deactivation systems, and direct-to-manufacturer prescription programs that serve community health, pharmacy benefit, and emergency response initiatives. Issuing bodies include state health and human services agencies (Texas Health and Human Services Commission), state procurement offices administering cooperative purchasing vehicles (Minnesota Department of Administration Office of State Procurement through MMCAP), and county health departments (Seminole County, Florida). The pharmaceutical and OTC procurement activity spans manufacturers, wholesaler-channel vendors, and pharmacy benefit program participants required to meet cGMP, Drug Supply Chain Security Act compliance, E-Verify verification, and FDA regulatory requirements.

Recent procurement activity centers in Florida, Minnesota, Oregon, and Texas. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Minnesota Department of Administration through MMCAP posted RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with proposals due March 26, 2026, and contract effectiveness July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription program capabilities supporting self-insured employer and state agency pharmacy benefit arrangements. MMCAP awards are weighted 75 percent on price competitiveness, with vendors paying a 3 percent administrative fee and subject to performance penalties of $200 to $1,500 per violation.